DG172 (dihydrochloride) Property

storage temp. 

Store at -20°C

solubility 

≤20mg/ml in ethanol;25mg/ml in DMSO;25mg/ml in dimethyl formamide

form 

crystalline solid

color 

Light yellow to yellow

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

DG172 (dihydrochloride) Chemical Properties,Usage,Production

Description

DG-172 is an orally available inverse agonist of PPARβ/δ (IC₅₀ = 27 nM), down-regulating transcription of ANGPTL4 in mouse myoblasts (IC₅₀ = 9.5 nM). It alters the differentiation of bone marrow cells, augmenting GM-CSF-induced development into subsets of mature and immature dendritic cells. Inverse agonists of PPARβ/δ, including DG-172, inhibit cancer cell invasion through suppression of ANGPTL4 expression.

Uses

DG 172 Dihydrochloride is a potent peroxisome proliferator-activated receptor agonist and inhibit Angptl4 gene expression in mouse myoblasts.

References

[1]. lieber s, scheer f, meissner w, et al. (z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (dg172): an orally bioavailable pparβ/δ-selective ligand with inverse agonistic properties. j med chem. 2012 mar 22;55(6):2858-68.
[2]. lieber s, scheer f, finkernagel f, et al. the inverse agonist dg172 triggers a pparβ/δ-independent myeloid lineage shift and promotes gm-csf/il-4-induced dendritic cell differentiation. mol pharmacol. 2015 feb;87(2):162-73.
[3]. adhikary t, brandt dt, kaddatz k, et al. inverse pparβ/δ agonists suppress oncogenic signaling to the angptl4 gene and inhibit cancer cell invasion. oncogene. 2013 oct 31;32(44):5241-52.